CREB3L1 and breast neoplasm: Overall, CREB3L1 was lost in 31 % (67/213) of the human breast tumor samples analyzed, but importantly CREB3L1 was lost from a much larger fraction of the high-grade (8 and 9) metastatic breast tumors (51 % of grade 8 and 73 % of grade 9 breast tumors; p = 0.001).